ReviewPediatric research2026
Impact of altered heme oxygenase-1 in caring for preterm neonates: navigating the unknown.
Review in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heme-oxygenase-1 (HO-1) is a key regulatory factor in organ development, organ function, cellular metabolism, heme processing, and bilirubin production. HO-1 homeostasis is crucial for healthy pregnancy and fetus. Dysregulation of HO-1 adversely affects placentation, yolk sac development, cardiovascular development, immune function, angiogenesis, microcirculation, alters the oxidoreductive balance, and is associated with adverse respiratory outcomes and necrotizing enterocolitis. The impact of HO-1 on neonatal neurodevelopment is unknown and is currently being investigated by our laboratory. In this review, we will discuss the morbidities associated with HO-1 dysregulation and importantly, we will navigate the unknown. We will highlight how infection or inflammation affect HO-1 homeostasis, its implications on neonatal morbidities at the limits of viability, summarize the relevant basic, translational, clinical and epidemiologic studies. We will conclude with proposing new approaches for the future, filling the gap between what is currently known and unknown. IMPACT: What does this article add to the existing literature? HO-1 pathway is relevant to pregnancy, fetus, neonatal, and later life outcomes. Provides comprehensive organ systems-based evaluation of Heme-oxygenase-1 in pregnancy, fetus, extreme preterm, and periviable neonates. Highlights how environmental factors, including infection, inflammation resulting in systemic dysregulation of HO-1 affects major neonatal morbidities. Underscores that novel investigations to close the knowledge gap are forthcoming to transform the HO-1 field.
Identifiers
42919829What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.